A plain language summary of the TROPHY-U-01 study (Cohort 2): use of sacituzumab govitecan after immunotherapy in people with metastatic urothelial cancer who cannot take cisplatin-based chemotherapy.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI:10.1080/14796694.2025.2548757

Petros Grivas, Scott T Tagawa, Rohit K Jain, Manojkumar Bupathi, Arjun Balar, Arash Rezazadeh Kalebasty, Saby George, Phillip Palmbos, Luke Nordquist, Daniel P Petrylak, Nancy Davis, Cora N Sternberg, Neeraj Agarwal, Chandler Park, Julia Tonelli, Huafeng Zhou, Rick Bangs, Yohann Loriot

引用次数: 0

查看原文本刊更多论文

TROPHY-U-01研究（队列2）的简单语言总结：转移性尿路上皮癌患者不能接受顺铂化疗，免疫治疗后使用sacituzumab govitecan。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.